Relmada reports Q2 net loss $12.9M; cash $217.7M; NDV-01 IND on track for YE26

RELMADA THERAPEUTICS, INC.

Net loss of $12.9M ($0.11/share) vs $9.9M loss in Q2 2025; R&D expense rose to $8.4M from $2.8M.
Cash, equivalents, and short-term investments of $217.7M as of June 30, 2026, expected to fund operations through 2029.
NDV-01 IND filing expected by year-end 2026; Phase 3 RESCUE program initiation upon IND clearance.
Sepranolone IND filing expected by year-end 2026; Phase 2 proof-of-concept in Prader-Willi Syndrome upon clearance.
Appointed Bipin Dalmia as Chief Business Officer; added to Russell 2000 and 3000 indexes in June 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.